{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:35:20Z","timestamp":1792985720679,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104893","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T23:41:02Z","timestamp":1755128462000},"page":"104893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Effectiveness and safety of PARP inhibitors in ovarian cancer: An umbrella review of systematic reviews and meta-analyses"],"prefix":"10.1016","volume":"215","author":[{"given":"Chih-Chen","family":"Tzang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewen Shengyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-An","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky Fu-Hsuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Show","family":"Tzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-1249","authenticated-orcid":false,"given":"Tsai-Ching","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104893_bib1","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.critrevonc.2025.104893_bib2","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104893_bib3","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision Medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104893_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1147717","article-title":"Anti-angiogenic therapy in ovarian cancer: current understandings and prospects of precision Medicine","volume":"14","author":"Mei","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.104893_bib5","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2018\/e450s","article-title":"Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management","volume":"73","author":"da Cunha Colombo Bonadio","year":"2018","journal-title":"Clinics"},{"key":"10.1016\/j.critrevonc.2025.104893_bib6","article-title":"Efficacy and safety of PARP inhibitors in prostate cancer: an umbrella review of systematic reviews and meta-analyses","volume":"207","author":"Tzang","year":"2025","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084203","article-title":"Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104893_bib9","first-page":"100","article-title":"Update on PARP inhibitors for the treatment of ovarian cancer","volume":"23","author":"Liu","year":"2025","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104893_bib11","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib12","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1038\/s41467-022-34109-8","article-title":"Reversion mutations in germline BRCA1\/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies","volume":"13","author":"Murciano-Goroff","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104893_bib13","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5.","article-title":"Chapter V: overviews of reviews [last updated August 2023","author":"Pollock","year":"2024"},{"key":"10.1016\/j.critrevonc.2025.104893_bib14","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2025.104893_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106927","article-title":"DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review","volume":"196","author":"Phan","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.critrevonc.2025.104893_bib16","first-page":"Cd007929","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","volume":"2","author":"Tattersall","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104893_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100632","article-title":"Maintenance therapy with a poly (ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: updated individual patient data and trial-level meta-analysis","volume":"77","author":"Gulia","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104893_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104229","article-title":"The impact of PARP inhibitors in the whole scenario of ovarian cancer management: a systematic review and network meta-analysis","volume":"193","author":"Staropoli","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104893_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J. Ovarian Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104893_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/cco-22-114","article-title":"Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis","volume":"12","author":"Batalini","year":"2023","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.638295","article-title":"Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and Meta-Analysis","volume":"11","author":"Ren","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib22","first-page":"A103","article-title":"Efficacy of parp inhibitors maintenance in older patients with ovarian cancer: a meta-analysis. int j gynecol cancer","volume":"31","author":"Maiorano","year":"2021"},{"key":"10.1016\/j.critrevonc.2025.104893_bib23","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.2147\/CMAR.S191107","article-title":"Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials","volume":"11","author":"Ma","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2025.104893_bib24","article-title":"Comparison of the efficacy and safety of PARP inhibitors as a monotherapy for Platinum-Sensitive recurrent ovarian cancer: a network Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104893_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2023.2171282","article-title":"Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis","volume":"43","author":"Li","year":"2023","journal-title":"J. Obstet. Gynaecol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104893_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294647","article-title":"Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: a meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"PLOS ONE"},{"key":"10.1016\/j.critrevonc.2025.104893_bib27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3389\/fonc.2020.00958","article-title":"Efficacy and prognostic factors for PARP inhibitors in patients with ovarian cancer","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103145","article-title":"Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"157","author":"Hao","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2023.03.035","article-title":"Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis","volume":"187","author":"Peters","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104893_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14737140.2024.2350105","article-title":"Efficacy and safety of neoadjuvant therapy for HR-positive\/HER2-negative early breast cancer: a Bayesian network meta-analysis","volume":"24","author":"Chen","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104893_bib31","article-title":"Systematic review of olaparib in the treatment of recurrent platinum sensitive ovarian cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib32","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/ijgc-2020-001373","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis","volume":"30","author":"Gong","year":"2020","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104893_bib33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000486418","article-title":"PARP (Poly(ADP-Ribose) polymerase) inhibitors in Platinum-Sensitive recurrent ovarian cancer: a Meta-Analysis of randomized controlled trials","volume":"41","author":"Al Hadidi","year":"2018","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.104893_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101909","article-title":"Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to BRCA mutational status","volume":"80","author":"Tomao","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104893_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/1120009X.2022.2073161","article-title":"The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis","volume":"35","author":"Skelin","year":"2023","journal-title":"J. Chemother."},{"key":"10.1016\/j.critrevonc.2025.104893_bib36","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.18632\/aging.202724","article-title":"PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival","volume":"13","author":"Shao","year":"2021","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104893_bib37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12957-023-03027-4","article-title":"Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials","volume":"21","author":"Purwar","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib38","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/CMAR.S169558","article-title":"The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2025.104893_bib39","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/DDDT.S164553","article-title":"Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.critrevonc.2025.104893_bib40","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.18632\/oncotarget.5367","article-title":"Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Bao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104893_bib41","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1007\/s12325-019-01106-1","article-title":"Comparison of PARPis with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: a network Meta-Analysis","volume":"36","author":"Feng","year":"2019","journal-title":"Adv. Ther."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104893_bib42","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.3390\/cancers14235955","article-title":"Beyond platinum, ICIs in metastatic cervical cancer: a systematic review","volume":"14","author":"Maiorano","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104893_bib43","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1097\/MS9.0000000000003186","article-title":"Assessment of safety of niraparib maintenance therapy in epithelial ovarian cancer: an updated systematic review and meta-analysis of randomized control trials","volume":"87","author":"Khan","year":"2025","journal-title":"Ann. Med Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104893_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-024-03771-w","article-title":"Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis","volume":"81","author":"Jin","year":"2025","journal-title":"Eur. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104893_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12885-025-13579-1","article-title":"Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis","volume":"25","author":"Fu","year":"2025","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104893_bib46","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.31557\/APJCP.2025.26.6.1931","article-title":"Impact of olaparib, niraparib, rucaparib therapies on newly diagnosed and relapsed ovarian cancer -Systematic review and Meta-Analysis","volume":"26","author":"Devi","year":"2025","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104893_bib47","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3390\/jcm14051776","article-title":"Efficacy and safety of combination therapy with PARP inhibitors and Anti-Angiogenic agents in ovarian cancer: a systematic review and Meta-Analysis","volume":"14","author":"Barad\u00e1cs","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2025.104893_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1477105","article-title":"Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis","volume":"14","author":"Huang","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1372077","article-title":"Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials","volume":"15","author":"Wei","year":"2024","journal-title":"Front Pharm."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104893_bib50","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.3390\/cancers14235955","article-title":"Beyond platinum, ICIs in metastatic cervical cancer: a systematic review","volume":"14","author":"Maiorano","year":"2022","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104893_bib51","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2217\/bmm-2020-0891","article-title":"PARP1 as a prognostic biomarker for human cancers: a meta analysis","volume":"15","author":"Huang","year":"2021","journal-title":"Biomark. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104893_bib52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.31083\/j.ceog5009185","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in neoadjuvant chemotherapy for Triple-Negative breast cancer: a systematic review and Meta-Analysis","volume":"50","author":"Li","year":"2023","journal-title":"Clin. Exp. Obstet. Gynecol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104893_bib53","article-title":"Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: a systematic review and meta-analysis","volume":"41","author":"Stecca","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.104893_bib55","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40273-021-01121-7","article-title":"Economic and humanistic burden of Triple-Negative breast cancer: a systematic literature review","volume":"40","author":"Huang","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.critrevonc.2025.104893_bib56","article-title":"Comparison of the efficacy and safety of PARP inhibitors as a monotherapy for Platinum-Sensitive recurrent ovarian cancer: a network Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1354427","article-title":"BRCA1\/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges","volume":"14","author":"Collet","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib58","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1541-7786.MCR-13-0672","article-title":"Transcriptional roles of PARP1 in cancer","volume":"12","author":"Schiewer","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104893_bib59","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to Platinum-Containing neoadjuvant chemotherapy in patients with Triple-Negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104893_bib60","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as First-Line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104893_bib61","unstructured":"LLC MSD. Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001\/KEYLYNK-001\/ENGOT-ov43\/GOG-3036). 2024 2024\u201311\u201319 [cited 2025 05 27]; Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT03740165\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104893_bib62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS-STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104893_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100744","article-title":"Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer","volume":"55","author":"Chiappa","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.critrevonc.2025.104893_bib64","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104893_bib65","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O'Malley","year":"2023","journal-title":"Target Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:25:33Z","timestamp":1792985133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":65,"alternative-id":["S1040842825002811"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104893","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of PARP inhibitors in ovarian cancer: An umbrella review of systematic reviews and meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104893"}}